Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

960.02 +19.82 (+2.11%)
Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,555,075
Open 945.00
Bid (Size) 955.37 (1)
Ask (Size) 961.50 (5)
Prev. Close 940.20
Today's Range 940.51 - 961.00
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities

Performance

YTD
+62.11%
+62.11%
1 Month
+19.37%
+19.37%
3 Month
+17.03%
+17.03%
6 Month
+22.75%
+22.75%
1 Year
+73.23%
+73.23%

More News

Read More
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Via Benzinga
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Via The Motley Fool
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Via Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Via The Motley Fool
Why Hims & Hers Health Stock Was Falling This Week
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Via The Motley Fool
Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender
Via Benzinga
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
Via Newsfile
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
Via The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
Via The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
Via The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Why Hims & Hers Health Stock Is Falling
Via Benzinga
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
Via The Motley Fool
Eli Lilly Slashes Zepbound Weight Loss Vial Prices By Up To 50% To Boost Access
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
Via Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.